Highlights • Hydroxychloroquine is an efficient candidate drug against COVID-19. • Oseltamivir can be prudently considered in combination therapy. • Drug repurposing is a promising way to combat SARS-CoV-2 infection. • Comparison of drug effects against COVID-19 is instructive in the pandemic. Coronavirus disease 19 (COVID-19) has posed serious threats to the general population. To relieve the crisis, a comparison of drug effects against COVID-19 is instructive. Between January 27, 2020 and March 21, 2020, a total of 333 patients treated with arbidol, corticosteroids, hydroxychloroquine, lopinavir/ritonavir, or oseltamivir monotherapy, having definite outcomes and serological antibody detection results, were retrospectively analyzed. The hydroxychloroquine group had a significantly reduced duration of hospital stay than the arbidol and corticosteroids groups. The oseltamivir group had a significantly shorter length of hospital stay than the arbidol, corticosteroids, and lopinavir/ritonavir groups. The hydroxychloroquine group had a significantly higher IgM titer than the other four groups and exhibited significantly higher IgG levels than the arbidol, lopinavir/ritonavir, and oseltamivir groups. Our findings indicated that hydroxychloroquine might have the potential for efficient COVID-19 management, while oseltamivir should be prudently considered in combination therapy.
【저자키워드】 COVID-19, Arbidol, oseltamivir, Corticosteroids, Lopinavir/ritonavir, Hydroxychloroquine, 【초록키워드】 Corticosteroid, Drug repurposing, IgM, pandemic, threat, SARS-COV-2 infection, combination therapy, outcome, Antibody detection, management, General population, coronavirus disease 19, monotherapy, serological, Hospital stay, hydroxychloroquine group, Effect, analyzed, significantly, indicated, reduced, exhibited, significantly higher, groups, four group, IgG level, patients treated, significantly shorter, 【제목키워드】 drug, retrospective,